Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tradingview has the HOD @.158 and Yahoo also has the HOD @.158
BDCI news out
CANNABIS CONSORTIUM AND ITS PARTNERS ACQUIRING EXCLUSIVE RIGHTS TO AN AWARD WINNING EDIBLE INFUSED CANDY COMPANY LOCATED IN CA.
https://ih.advfn.com/p.php?pid=nmona&article=77166216
BDCI nice buy area imo
BDCI getting close to a big move up
What's the Authorized here?
SKLN premarket news with nice hits @.248
http://www.marketwatch.com/story/skyline-medical-completes-warrant-exchange-offer-2016-04-25
SKLN someone is loading......$60K bid @.241
grrr.....got this song stuck in my head now.....lol
PACD on the move
TPIV news
https://www.morningstar.com/news/pr-news-wire/PRNews_20160407enUK201604079950/tapimmune-completes-gmp-manufacturing-and-release-of-tpiv-200-vaccine.html
TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine
PR Newswire
JACKSONVILLE, Florida, April 7, 2016
JACKSONVILLE, Florida, April 7, 2016 /PRNewswire/ --
Doses for use at Mayo Clinic and other clinical sites
Stable, easily reconstituted product contains five folate receptor alpha peptides in a single vial
TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today it has successfully completed formulation development, scale-up, GMP (Good Manufacturing Practice) manufacturing, and the release of TPIV 200, its multi-epitope folate receptor peptide vaccine for breast and ovarian cancer. The manufactured product contains five peptide antigens freeze dried in a single vial, ready for injection after reconstitution and addition of granulocyte-macrophage colony-stimulating factor (GM-CSF). TPIV 200 doses are now available for the upcoming Phase II clinical trials in both triple negative breast cancer and ovarian cancer.
The initiation of Phase II clinical trials for TPIV 200 is the result of a successful Phase I study in ovarian and breast cancer which demonstrated that the vaccine was safe, well-tolerated, and generated a robust and lasting folate receptor alpha-specific T-cell response for most patients.
TapImmune has announced its plans to initiate, in 2016, several clinical trials with TPIV 200 vaccine including: a) a 280 patient Phase II trial in triple-negative breast cancer funded by a grant from the U.S Department of Defense (DOD) to the Mayo Clinic; b) a combination trial with a checkpoint inhibitor in ovarian cancer; and, c) at least two additional trials funded and administered by TapImmune.
"The successful release of our folate receptor vaccine represents an important milestone in the progression of TapImmune product pipeline and its technologies. The improved process achieved a formulation that may be reliably manufactured, is easy to prepare and administer to the patient at bed-side, while also being cost-competitive," stated Dr. Glynn Wilson, Chairman and CEO of TapImmune. "The experience we gained in completing this work is being directly applied to our formulation work for a second product in our pipeline, the HER2/Neu T-cell vaccine. Our objective is to file an investigational new drug (IND) application with the U.S. Food and Drug Administration for HER2/Neu vaccine trials in the next 12 months."
"The release of this first GMP batch of vaccine product will supply the first Tapimmune sponsored Phase II trial in breast cancer, for which at least six clinical sites are currently being screened and initiated, and also the Mayo Clinic sponsored Phase II study funded by the DOD," commented Patrick Yeramian, MD, Chief Medical Officer of TapImmune.
About TapImmune Inc.
TapImmune Inc. is an immune-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at http://www.tapimmune.com for details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
CONTACTS:
TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1(866)-359-7541
SOURCE TapImmune Inc.
Great call on the top here. My first target was in the .90s as well. I'm still holding though. The 50 crossed the 100 today and is on track to cross the 200 within the next two days. There is a gap @.724 so that might get filled. Also, R2 on the fib is @.722. The last time the 50 crossed the 100 it ran +60%....I'm still holding for the pop. My entry....risk/reward I'm feeling pretty safe here. We'll see how she goes.
Picked up a few KGNX today....as always, great alert. Have a great weekend everyone.
TPIV looking good here Chance....Nice buying going into the weekend. A close above the ma100 @.705 on the weekly would be very bullish imo.
Thanks Strong....holding for the boing ;)
TPIV.....I picked up a starter today. Looks like this one is just getting started. Imo, the run really hasn't even started yet. Looking on the weekly, the ma100 is at .70
Looks like within 10 days we should see all golden crosses cross over. Unless, of course, something changes and we breakdown.
I'm watching for continued strong volume and a break of that .70 to buy more, otherwise I might add on any dips.
I included the zoom thumbnail to see the congested ma's better.
TPIV on watch for breakout
After posting I soon realized that I set someone up for some funnies.
np :)
Nice board here....will be following
ISBG bid stacking up....6's getting some hits....pincher play
ISBG could breakout soon...pincher
Link please.
Close to the entire Authorized has traded over .0006 since 3/9
SHOM .005 is breakout area....IMO
Morning Strong.....SHOM bid building...looking like it could run today
I'm getting fed up with stockcharts.
Stockcharts chart request....Please, everyone request a chart for DIDG. You don't have to be a member to request.
http://stockcharts.com/support/symbolrequest.html
Picked up some ISBG today as well
In SHOM for a few
OH, that's funny........goooo DIDG!!!
DIDG +50% on 60M
Picked up a few DIDG
Good morning all....USAR news out this morning:
https://finance.yahoo.com/news/chron-organization-announces-chief-administrative-140000725.html
The Chron Organization Announces New Chief Administrative and Compliance Officer
Marketwired The Chron Organization
17 minutes ago
DALLAS, TX--(Marketwired - Mar 8, 2016) - The Chron Organization, Inc. (OTC PINK: USAR), announced today that Mr. Doug McKinnon has joined the Company as its new Chief Administrative and Compliance Officer. Mr. McKinnon will oversee the Company's compliance matters, corporate filing obligations, establishment and management of internal policies and procedures and assist with the development of operating processes towards ensuring a proper system of internal controls.
Over the past two years, Mr. McKinnon has served as Executive Vice President, Chief Financial Officer and as a member of the Board of Directors of Surna, Inc., a provider of climate control and environmental systems. Prior to Surna, he served as President of a private oil & gas technology company.
Mr. McKinnon has more than thirty years of experience which includes advisory and operation knowledge across a broad spectrum of industry sectors, including oil and gas, technology, and communications. He has served in C-level positions in both private and public sectors, including Chairman and CEO of an American Stock Exchange traded company, Vice President of a $12 billion market cap NASDAQ-traded company for which the management team raised over $2.2 billion, CFO of several publicly held US, Canadian and Australian companies, and CEO/CFO of various other private enterprises. As an entrepreneur, Mr. McKinnon has been involved in organizations ranging from start-up companies using venture capital funding to publicly traded, institutional investor-backed companies.
Mr. McKinnon attended Texas Christian University. He worked for nine years as a CPA in the SEC and the oil and gas practice section of Coopers & Lybrand (now PricewaterhouseCoopers). Additionally, he has extensive merger & acquisition and turnaround experience.
Byron Young, Chairman of The Chron Organization, stated, "Doug gets the kind of culture that we are trying to create and his depth of experience is second to none. We are looking forward to have him on our management team."
Alex Rodriguez, President of Chron, said, "Our goal is to become a fully reporting company as soon as possible. The addition of McKinnon to our management team is a major step in that direction. We are excited to be working alongside with him."
ABOUT THE CHRON ORGANIZATION
The Chron Organization, Inc. (OTC PINK: USAR), is a 21st century services company providing state-of-the-art Smart Home technologies and the next generation in energy utility services. The Company provides homeowners with the latest in security, monitoring and automation controls enabling homeowners to have a Smart Home at an affordable price. Chron combines that with its cloud-based, green energy services, reducing both their carbon footprint and their monthly energy expense. The Company's plan is to capture 5% of homeowners, while dramatically reducing the nation's peak electricity demand. To learn more, please visit the website at www.chronhomeservices.com.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCMarkets.com.
Contact:
INVESTORS & MEDIA CONTACT:
Email: Email Contact
Phone: (469) 626-5275
Investor Relations:
The Eversull Group, Inc.
Jack Eversull
President
972-571-1624
214-469-2361 fax
PACD nice move
USAR .0148....could break .015 today
BBRD, ICNV, GEQU charts look good just need some good volume.